Home / Health / New 'Trojan Horse' Drug Targets Obesity Differently
New 'Trojan Horse' Drug Targets Obesity Differently
27 May
Summary
- German researchers developed a novel 'Trojan horse' obesity drug.
- This drug targets multiple pathways, fixing blood sugar and insulin sensitivity.
- Early mouse tests show it outperforms current weight loss leaders.
Researchers in Germany have engineered a novel 'Trojan horse' drug for obesity, marking a significant advancement beyond current treatments like Ozempic and Wegovy. Published in Nature, the study details how this hybrid molecule mimics GLP-1 and GIP hormones to deliver a compound called lanifibranor directly into targeted cells.
This targeted delivery mechanism minimizes systemic side effects by releasing lanifibranor, which activates PPAR switches involved in fat burning and energy management. The experimental drug successfully reduced appetite and weight in obese mice, while also enhancing blood sugar control and insulin sensitivity more effectively than other tested methods.
This innovative approach targets five pathways simultaneously, offering a potent strategy against obesity. While early results in mice are promising, human trials are still years away. This development coincides with advancements in multi-hormone drugs, signaling a shift towards comprehensive treatments for obesity as a complex chronic disease.
